Form 4/A for STLN Starling Oncology, Inc.
Accepted 2022-12-30 00:00:00 ET · period of report 2022-11-17 · accession 0001799191-22-000060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-12-30 | 2022-11-17 | STLN | BARASCH RICHARD A | Dir | A - Grant | $0.00 | +65.2K | 207.2K | +46% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-17 | A | A | 65,174 | $0.00 | 207,193 | D | — | — | (F1) This amendment is filed to correct the number of restricted stock units granted due to an administrative error in applying the grant amount calculations. (F2) Represents restricted stock units that vest in full on May 17, 2023, subject to continued service with the Company through such vesting date. |